Log in

Protagonist Therapeutics News Headlines (NASDAQ:PTGX)

$11.59
-0.48 (-3.98 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$11.32
Now: $11.59
$12.11
50-Day Range
$10.81
MA: $13.25
$16.07
52-Week Range
$5.49
Now: $11.59
$16.67
Volume79,831 shs
Average Volume163,215 shs
Market Capitalization$304.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72

Headlines

Protagonist Therapeutics (NASDAQ PTGX) News Headlines

Source:
DateHeadline
$5.75 Million in Sales Expected for Protagonist Therapeutics Inc (NASDAQ:PTGX) This Quarter$5.75 Million in Sales Expected for Protagonist Therapeutics Inc (NASDAQ:PTGX) This Quarter
www.americanbankingnews.com - October 19 at 4:58 AM
 Analysts Expect Protagonist Therapeutics Inc (NASDAQ:PTGX) Will Announce Earnings of -$0.75 Per Share Analysts Expect Protagonist Therapeutics Inc (NASDAQ:PTGX) Will Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - October 17 at 5:29 AM
Protagonist Therapeutics Inc (NASDAQ:PTGX) Given Average Rating of "Buy" by BrokeragesProtagonist Therapeutics Inc (NASDAQ:PTGX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 16 at 1:32 AM
Protagonist Therapeutics Inc (NASDAQ:PTGX) Sees Large Increase in Short InterestProtagonist Therapeutics Inc (NASDAQ:PTGX) Sees Large Increase in Short Interest
www.americanbankingnews.com - October 15 at 6:11 AM
The Protagonist Therapeutics (NASDAQ:PTGX) Share Price Is Down 45% So Some Shareholders Are Getting WorriedThe Protagonist Therapeutics (NASDAQ:PTGX) Share Price Is Down 45% So Some Shareholders Are Getting Worried
finance.yahoo.com - October 2 at 4:57 PM
Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific MeetingProtagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
finance.yahoo.com - October 1 at 3:49 PM
Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2
finance.yahoo.com - September 25 at 8:46 AM
Protagonist Therapeutics Inc (NASDAQ:PTGX) Expected to Announce Earnings of -$0.75 Per ShareProtagonist Therapeutics Inc (NASDAQ:PTGX) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - September 24 at 10:43 AM
Protagonist Therapeutics Reports Granting of Inducement AwardsProtagonist Therapeutics Reports Granting of Inducement Awards
finance.yahoo.com - September 4 at 5:15 PM
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare ConferenceProtagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference
finance.yahoo.com - September 3 at 5:42 PM
Does Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Salary Reflect Performance?Does Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Salary Reflect Performance?
finance.yahoo.com - August 27 at 5:52 PM
BRIEF-Protagonist Therapeutics Reports Second Quarter 2019 Financial ResultsBRIEF-Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
www.msn.com - August 7 at 10:39 PM
Protagonist Therapeutics Reports Second Quarter 2019 Financial ResultsProtagonist Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 7 at 10:57 AM
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue EstimatesProtagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 7 at 10:57 AM
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 StudyOral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
finance.yahoo.com - August 1 at 5:44 PM
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - July 30 at 6:00 PM
Should You Be Worried About Insider Transactions At Protagonist Therapeutics, Inc. (NASDAQ:PTGX)?Should You Be Worried About Insider Transactions At Protagonist Therapeutics, Inc. (NASDAQ:PTGX)?
finance.yahoo.com - July 11 at 5:41 PM
Here’s What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)Here’s What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
finance.yahoo.com - June 23 at 4:49 PM
Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare ConferenceProtagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference
finance.yahoo.com - June 17 at 11:20 AM
New finance chief at ProtagonistNew finance chief at Protagonist
seekingalpha.com - May 29 at 5:31 PM
Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial OfficerProtagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer
finance.yahoo.com - May 29 at 5:31 PM
Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call TranscriptProtagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 15 at 10:08 PM
Protagonist IBD candidate shows positive action in early-stage study; shares up 2%Protagonist IBD candidate shows positive action in early-stage study; shares up 2%
seekingalpha.com - May 14 at 5:28 PM
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 StudyOral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
finance.yahoo.com - May 14 at 10:49 AM
Protagonist expands PTG-200 deal with Janssen; shares up 13%Protagonist expands PTG-200 deal with Janssen; shares up 13%
seekingalpha.com - May 8 at 5:07 PM
Protagonist Therapeutics Reports First Quarter 2019 Financial ResultsProtagonist Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 8 at 10:32 AM
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor AntagonistsProtagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
www.marketwatch.com - May 8 at 10:32 AM
What You Must Know About Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Beta ValueWhat You Must Know About Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Beta Value
finance.yahoo.com - May 8 at 10:32 AM
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue EstimatesProtagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 8 at 10:32 AM
Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019
finance.yahoo.com - May 7 at 10:27 AM
Earnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to DeclineEarnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to Decline
finance.yahoo.com - May 1 at 5:10 PM
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9
finance.yahoo.com - April 1 at 12:06 PM
Protagonist Therapeutics Inc.Protagonist Therapeutics Inc.
www.barrons.com - March 15 at 4:56 PM
Protagonist Therapeutics, Inc.s (PTGX) CEO Dinesh Patel on Q4 2018 Results - Earnings Call TranscriptProtagonist Therapeutics, Inc.'s (PTGX) CEO Dinesh Patel on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 13 at 10:04 AM
Edited Transcript of PTGX earnings conference call or presentation 12-Mar-19 8:30pm GMTEdited Transcript of PTGX earnings conference call or presentation 12-Mar-19 8:30pm GMT
finance.yahoo.com - March 13 at 10:04 AM
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial ResultsProtagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 12 at 9:04 PM
Protagonist Therapeutics: 4Q Earnings SnapshotProtagonist Therapeutics: 4Q Earnings Snapshot
finance.yahoo.com - March 12 at 9:04 PM
Protagonist Therapeutics, Inc. (PTGX)Protagonist Therapeutics, Inc. (PTGX)
finance.yahoo.com - March 5 at 11:29 AM
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial ResultsProtagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 5 at 11:29 AM
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
finance.yahoo.com - February 21 at 11:59 AM
Dosing underway in mid-stage study of Protagonists PTG-300 in beta thalassemiaDosing underway in mid-stage study of Protagonist's PTG-300 in beta thalassemia
seekingalpha.com - January 9 at 9:48 AM
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta ThalassemiaProtagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
finance.yahoo.com - January 9 at 9:48 AM
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and PharmacologyProtagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology
www.marketwatch.com - January 7 at 9:29 AM
Protagonist finance chief to bid adieuProtagonist finance chief to bid adieu
seekingalpha.com - January 1 at 8:57 AM
Who Has Been Buying Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares?Who Has Been Buying Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares?
finance.yahoo.com - December 20 at 4:52 PM
Protagonist launches early-stage study of integrin antagonist for IBDProtagonist launches early-stage study of integrin antagonist for IBD
seekingalpha.com - December 13 at 8:58 AM
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
finance.yahoo.com - December 13 at 8:58 AM
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare ConferenceProtagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 5 at 9:27 AM
Protagonist down 15% after bailing on IBD candidate PTG-100Protagonist down 15% after bailing on IBD candidate PTG-100
seekingalpha.com - November 28 at 4:43 PM
Protagonist Therapeutics (PTGX) Announces New Development Candidate PN-10943 for the Treatment of IBDProtagonist Therapeutics (PTGX) Announces New Development Candidate PN-10943 for the Treatment of IBD
www.streetinsider.com - November 28 at 9:32 AM
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: Swap

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel